Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lyra Therapeutics (LYRA) Return on Assets (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed Return on Assets for 5 consecutive years, with 0.68% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Assets rose 44.0% to 0.68% in Q3 2025 year-over-year; TTM through Sep 2025 was 0.68%, a 44.0% increase, with the full-year FY2024 number at 0.89%, down 40.0% from a year prior.
  • Return on Assets was 0.68% for Q3 2025 at Lyra Therapeutics, up from 0.71% in the prior quarter.
  • In the past five years, Return on Assets ranged from a high of 0.44% in Q3 2022 to a low of 1.3% in Q1 2025.
  • A 5-year average of 0.73% and a median of 0.63% in 2023 define the central range for Return on Assets.
  • Peak YoY movement for Return on Assets: crashed -81bps in 2024, then soared 44bps in 2025.
  • Lyra Therapeutics' Return on Assets stood at 0.71% in 2021, then soared by 32bps to 0.48% in 2022, then increased by 1bps to 0.48% in 2023, then plummeted by -170bps to 1.29% in 2024, then skyrocketed by 47bps to 0.68% in 2025.
  • Per Business Quant, the three most recent readings for LYRA's Return on Assets are 0.68% (Q3 2025), 0.71% (Q2 2025), and 1.3% (Q1 2025).